Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of DYNE-101 in myotonic dystrophy type 1
2025-522957-20-00Phase 3Authorised
- Sponsor
- Dyne Therapeutics
- Start
- May 2026
- Modality
- Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) comparing DYNE-101 with Placebo (2 arms). Primary endpoint: 5×STS time. Planned start May 2026; status: authorised.
02
Drugs
zeleciment basivarsen
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on 2025-522957-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522957-20-00.